AR019096A1 - Composicion de liberacion controlada que comprende levosimendan y un polimero que forma gel hidrofilico - Google Patents

Composicion de liberacion controlada que comprende levosimendan y un polimero que forma gel hidrofilico

Info

Publication number
AR019096A1
AR019096A1 ARP990101869A ARP990101869A AR019096A1 AR 019096 A1 AR019096 A1 AR 019096A1 AR P990101869 A ARP990101869 A AR P990101869A AR P990101869 A ARP990101869 A AR P990101869A AR 019096 A1 AR019096 A1 AR 019096A1
Authority
AR
Argentina
Prior art keywords
levosimendan
understanding
polymer
composition
controlled release
Prior art date
Application number
ARP990101869A
Other languages
English (en)
Spanish (es)
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR019096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR019096A1 publication Critical patent/AR019096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
ARP990101869A 1998-04-23 1999-04-22 Composicion de liberacion controlada que comprende levosimendan y un polimero que forma gel hidrofilico AR019096A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia

Publications (1)

Publication Number Publication Date
AR019096A1 true AR019096A1 (es) 2001-12-26

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101869A AR019096A1 (es) 1998-04-23 1999-04-22 Composicion de liberacion controlada que comprende levosimendan y un polimero que forma gel hidrofilico

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
SK15542000A3 (sk) 2001-08-06
WO1999055305A2 (en) 1999-11-04
ATE258425T1 (de) 2004-02-15
GEP20032906B (en) 2003-02-25
CZ20003780A3 (en) 2001-05-16
UA68376C2 (en) 2004-08-16
TWI224507B (en) 2004-12-01
ES2215379T3 (es) 2004-10-01
HRP20000704B1 (hr) 2009-11-30
YU63900A (sh) 2003-07-07
MXPA00010367A (es) 2002-06-04
RS49962B (sr) 2008-09-29
AU3524699A (en) 1999-11-16
SI1071397T1 (en) 2004-06-30
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
US7045147B1 (en) 2006-05-16
SK285427B6 (sk) 2007-01-04
HUP0101458A2 (hu) 2002-03-28
EP1071397B1 (en) 2004-01-28
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
AU756641B2 (en) 2003-01-16
PL197447B1 (pl) 2008-03-31
CN1301163A (zh) 2001-06-27
NO329809B1 (no) 2010-12-20
PT1071397E (pt) 2004-06-30
JP4566402B2 (ja) 2010-10-20
ID27987A (id) 2001-05-03
CA2329234C (en) 2008-06-10
PL344078A1 (en) 2001-09-24
EE04220B1 (et) 2004-02-16
EA002829B1 (ru) 2002-10-31
FI980901A7 (fi) 1999-10-24
IL138951A (en) 2006-10-31
KR20010071172A (ko) 2001-07-28
JP2002512946A (ja) 2002-05-08
DE69914472T2 (de) 2004-11-11
BG64839B1 (bg) 2006-06-30
WO1999055305A3 (en) 1999-12-29
JP2010083900A (ja) 2010-04-15
EA200001098A1 (ru) 2001-04-23
NO20005313D0 (no) 2000-10-20
IL138951A0 (en) 2001-11-25
EE200000617A (et) 2002-06-17
BR9909869A (pt) 2000-12-19
CZ295194B6 (cs) 2005-06-15
KR100960597B1 (ko) 2010-06-07
TR200003102T2 (tr) 2001-02-21
FI980901A0 (fi) 1998-04-23
EP1071397A2 (en) 2001-01-31
HK1034032A1 (en) 2001-10-12
NZ507453A (en) 2003-02-28
NO20005313L (no) 2000-11-21
ZA200005632B (en) 2002-01-14
CO5070607A1 (es) 2001-08-28
DK1071397T3 (da) 2004-04-05
DE69914472D1 (de) 2004-03-04
CN1248691C (zh) 2006-04-05

Similar Documents

Publication Publication Date Title
EE02946B1 (et) (-)-[[4-(1,4,5,6-tetrahüdro-4-metüül-6-okso-3-püridasinüül)fenüül]-hüdrasono]propaan dinitriil, selle valmistamismeetod, soolad, kompositsioonid, vaheühendid ja kasutamine
CA2134972A1 (en) Anti-ischemic medicament
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
BR9902227A (pt) Artigo absorvente para ser usado internamente a outro artigo absorvente.
AU4144400A (en) Preventives/remedies for liver diseases
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
AR019096A1 (es) Composicion de liberacion controlada que comprende levosimendan y un polimero que forma gel hidrofilico
FR2704428B1 (fr) Utilisation de dérivés de la résorcine substitués en position(s) 4, 4 et 5 ou 4 et 6 dans des compositions cosmétiques ou dermopharmaceutiques à action dépigmentante.
BR0014168A (pt) Composições cosméticas contendo resinas de polissacarìdeo especìficas
NO981856L (no) Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling av amyotrof lateral sclerose
PL327060A1 (en) Application of 2-ethylhexyl alpha-cyano-beta,beta-diphemylacrylate to improve stability of cosmetic compositions containing p-methylbenzylibene camphor in combination with a derivative of dibenzoyl methane
EE04355B1 (et) Levosimendani kasutamine kopsuhüpertensiooni ravimi tootmises
DE60016038D1 (de) Neue verwendung von levosimendan
NO20016316L (no) Fremgangsmåte til å behandle eller forhindre kransarterietransplantasjonsvasospasme
NO20022954D0 (no) Anvendelse av bioaktive metabolitter av gepiron for behandling av psykologiske forstyrrelser
ATE272402T1 (de) Behandlung von septischem schock
WO2002047603A3 (en) Use of levosimendan for treating erictile dysfunction
NO985695L (no) Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt

Legal Events

Date Code Title Description
FG Grant, registration